



WELTRUZA™
(olanzapine) For extended-release
injectable suspension

318mg

425mg

531mg

October 9, 2026

Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements may include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: our ability to successfully develop and commercialize WELTRUZA™; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generic medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;
- our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate, and any effects of such developments on sales of our products and the pricing and availability of raw materials; effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, ongoing global conflicts, including in the Middle East and the war involving Iran and the war between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and/or integrate acquisitions successfully and cost-effectively; and our prospects and opportunities for growth if we sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business;
- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 ("OBBBA"), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, potentially altering utilization patterns and shifting negotiating leverage among payors, U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid for prescription medicines, including most-favored-nation pricing and related regulatory efforts; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to timely make payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement ("DPA") with the U.S. Department of Justice ("DOJ"); potential liability for intellectual property right infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs' reporting and payment obligations; compliance with sanctions and trade control laws; environmental risks and changes in governmental, investor and societal responses to climate change and sustainability related issues;
- other financial, economic and other risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; the impact of any failure to maintain effective internal control over our financial reporting; and our ability to achieve our aims as a result of directly listing our ordinary shares in lieu of the American Depositary Share (ADS) program;

and other factors discussed in this presentation and in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned "Risk Factors" and "Forward-looking Statements." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Agenda

1

Introduction

2

WELTRUZA Approval

3

Q&A



Richard Francis

President and Chief Executive Officer



Eric Hughes

EVP, Global R&D & Chief Medical Officer



Chris Fox

EVP, US Commercial Officer



Eli Kalif

EVP, Chief Financial Officer



Richard Francis

President and Chief Executive Officer

Pivot to Growth Acceleration is Delivering



Deliver on
growth engines



Step up
innovation



Sustain generics
powerhouse



Focus our
business

First Approval of Five Submissions in Five Years

Assets		Key anticipated milestone for 2026		Timing
duvakitug	>	UC/CD Phase 2 maintenance data	✓	H1'26
ecopipam	>	NDA accepted by the FDA with priority review	✓	H1'26
Anti-IL-15	>	Vitiligo Phase 1b topline results	✓	H1'26
		Celiac Phase 2a topline results	✓	H2'26
DARI (ICS/SABA)	>	Targeted completion of pivotal Phase 3 studies		H2'26
emrusolmin	>	Phase 2 futility analysis		H2'26
	>	FDA approval	✓	H2'26
Anti-PD-1/IL-2	>	Initial human data		H2'26



Eric Hughes, MD, PhD

Executive Vice President,
Global R&D & Chief Medical Officer


The Real-World Impact of Leaving Psychosis Untreated



Relapse drives progression


80% experience multiple relapses in first 5 years

Compliance is the challenge



Teva Well-Positioned For Launch

Significant U.S. market opportunity



Requirements to increase LAI penetration

- Deep understanding of the patient journey
- Demonstrated safety profile
- Go-to-market capabilities

WELTRUZA™ is Teva R&D Brought to Life



**Addressing unmet medical need
with proven science at high velocity**

First and Only Monthly Subcutaneous LAI With Proven Efficacy of Olanzapine

**PROVEN
EFFICACY OF
OLANZAPINE**



**Monthly Subcutaneous
Long-Acting Injection**

- **NO** loading dose
- **NO** oral supplementation
- **NO** post-injection monitoring

Filling a long-standing gap in care

96% Relapse-Free in Stabilized Patients

Relapse after stabilization (SOLARIS Period 2)





Relevant Links

[WELTRUZA Phase 3 SOLARIS Data Webcast](#)

[WELTRUZA Phase 3 SOLARIS Data Presentation](#)

[U.S. Prescribing Information](#)



We are all in for better health